2 months ago
VRTX
AnalystsTerence FlynnTerence Flynn's Stock Forecasts
AnalystsTerence Flynn
Sectors:
Analyst Ranking
Top 5%
#264 out of 5308 analysts
Average Return
+18.93%
Win Rate
66%90 out of 137
Risk vs Reward
Poor
Good
Terence Flynn's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Alumis IncALMS | +426.95% | $4.75 | $25.03 | 2025-08-15 - 2026-06-25 | Strong Buy |
Arcus Biosciences IncRCUS | +157.85% | $8.28 | $21.35 | 2025-05-09 - 2026-01-08 | Strong Buy |
Translate Bio IncTBIO1 | +147.91% | $15.07 | $37.36 | 2020-10-05 - 2021-09-14 | Strong Buy |
Blueprint Medicines CorpBPMC | +140.20% | $41.34 | $99.30 | 2017-03-13 - 2018-03-13 | Strong Buy |
Eli Lilly & CoLLY | +139.90% | $314.17 | $753.68 | 2023-03-01 - 2024-02-29 | Strong Buy |
Terence Flynn Analyst Color
Get additional color on Terence Flynn's coverage of popular stocks
2 months ago
ABBV
3 months ago
VRTX
3 months ago
RPRX
3 months ago
LLY
3 months ago
ALMS
4 months ago
VRTX
6 months ago
NRIX
6 months ago
ALMS
6 months ago
BMY
6 months ago
MRK
6 months ago
GPCR
6 months ago
AMGN
6 months ago
ABBV
7 months ago
LLY
7 months ago
LLY
9 months ago
LLY
a year ago
JNJ
a year ago
RPRX
a year ago
JNJ
a year ago
LLY
a year ago
ABBV
a year ago
JNJ
a year ago
LLY
a year ago
JNJ
Terence Flynn's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Amgen IncAMGN | 14 | Hold | $340.00 | -3.63% | Maintains | 17 days ago |
Biohaven LtdBHVN | 6 | Strong Buy | $18.00 | +17.34% | Maintains | a month ago |
Arcus Biosciences IncRCUS | 10 | Hold | $22.00 | -27.27% | Maintains | 2 months ago |
Vertex Pharmaceuticals IncVRTX | 6 | Strong Buy | $616.00 | +28.29% | Maintains | 2 months ago |
Abbvie IncABBV | 21 | Strong Buy | $278.00 | +14.34% | Maintains | 2 months ago |
Intellia Therapeutics IncNTLA | 6 | Hold | $15.00 | -6.43% | Maintains | 2 months ago |
United Therapeutics CorpUTHR | 12 | Hold | $519.00 | -4.49% | Maintains | 3 months ago |
Royalty Pharma PLCRPRX | 14 | Strong Buy | $63.00 | +15.19% | Maintains | 3 months ago |
Pfizer IncPFE | 22 | Hold | $28.00 | +18.29% | Maintains | 3 months ago |
Johnson & JohnsonJNJ | 29 | Strong Buy | $267.00 | +9.03% | Maintains | 3 months ago |
Eli Lilly & CoLLY | 23 | Strong Buy | $1,327.00 | +17.67% | Maintains | 3 months ago |
Biontech SeBNTX | 7 | Strong Buy | $126.00 | +40.00% | Maintains | 3 months ago |
Alumis IncALMS | 4 | Strong Buy | $38.00 | +51.82% | Maintains | 3 months ago |
Nurix Therapeutics IncNRIX | 7 | Strong Buy | $36.00 | +60.28% | Upgrades | 6 months ago |
Bristol Myers Squibb CoBMY | 11 | Strong Sell | $37.00 | -33.20% | Maintains | 6 months ago |
Merck & Co IncMRK | 19 | Hold | $102.00 | -18.69% | Maintains | 6 months ago |
Structure Therapeutics IncGPCR | 2 | Strong Buy | $125.00 | +159.07% | Maintains | 6 months ago |
Organon & CoOGN | 11 | Hold | $9.00 | -33.18% | Maintains | 8 months ago |
Arvinas IncARVN | 8 | Hold | $11.00 | N/A | Maintains | a year ago |
Crispr Therapeutics AgCRSP | 7 | Strong Sell | $32.00 | N/A | Maintains | a year ago |
Blueprint Medicines CorpBPMC | 5 | Strong Buy | $168.00 | N/A | Maintains | 2 years ago |
C4 Therapeutics IncCCCC | 5 | Hold | $8.00 | N/A | Maintains | 2 years ago |
Revance Therapeutics IncRVNC | 7 | Hold | $12.00 | N/A | Maintains | 3 years ago |
Neuehealth IncNEUE | 1 | Strong Buy | $2,880.00 | N/A | Initiates Coverage On | 5 years ago |
Biogen IncBIIB | 2 | Hold | $436.00 | N/A | Maintains | 5 years ago |
Translate Bio IncTBIO1 | 1 | Strong Buy | $342.00 | N/A | Initiates Coverage On | 6 years ago |
Acceleron Pharma IncXLRN | 2 | Hold | $40.00 | N/A | Upgrades | 8 years ago |
Alnylam Pharmaceuticals IncALNY | 1 | Strong Buy | N/A | N/A | Upgrades | 9 years ago |
Kyntra Bio IncKYNB | 1 | Hold | N/A | N/A | Downgrades | 9 years ago |
Bioverativ IncBIVV | 1 | Hold | N/A | N/A | Downgrades | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.